此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢股票經紀或其他註冊證券商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已出售或轉讓名下所有上海復宏漢霖生物技術股份有限公司之股份，應立即將本通函連同隨附之代表委任表格 送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並表明概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） (1)建議委任第四屆董事會董事 (2)建議委任第四屆監事會股東代表監事 (3)建議修訂公司章程 (4)建議修訂《股東大會議事規則》 (5)建議修訂《董事會議事規則》 (6)建議修訂《監事會議事規則》 (7)建議修訂《防止控股股東及其關聯方╱關連人士佔用公司資金制度》 (8)建議修訂《利潤分配管理制度》 及 臨時股東大會 ...

据悉，作为国内生物医药领军企业，复宏汉霖近年发展势头强劲，基本面持续夯实。公司目前已有 6 款 产品在中国获批、4 款实现海外上市，覆盖全球 50 余个国家和地区，累计惠及超 80 万患者。其中，公 司自研创新抗PD-1单抗汉斯状于近日完成印度首批发货，正式启程迈入全球人口第一大国。该产品上 市3年来，已在近40个国家和地区获批上市，覆盖全球近半数人口。资本市场表现同样亮眼，2025 年以 来公司股价累计上涨超200%，并于5 月纳入MSCI 全球小型股指数成分股，6 月 H 股全流通申请获中国 证监会受理，市场认可度持续提升。 在创新研发方面，复宏汉霖核心产品管线进展显著。公司潜在同类最佳 PD-L1 ADC HLX43 治疗晚期 NSCLC 的国际多中心 II 期临床研究已获中、美、澳、日等多国监管机构批准开展，且完成首例受试者 给药。HLX43 的 I 期临床数据于 2025 年美国临床肿瘤学会(ASCO)年会上首次亮相，初步疗效及安全性 表现亮眼，且开发进度领先全球，竞争优势显著。此外，创新型双通路抗 HER2 单抗 HLX22 针对 HER2 阳性晚期胃癌的国际多中心 III 期研究正稳步推进，有望 ...

Group 1 - The company proposed the reappointment of current executive director Dr. Zhu Jun for the fourth board of directors [1] - The company suggested the reappointment of current non-executive directors Mr. Wenjie Zhang, Mr. Chen Qiyu, Ms. Guan Xiaohui, and Dr. Xingli Wang for the fourth board of directors [1] - The company recommended the reappointment of current independent non-executive directors Mr. Su Deyang, Dr. Chen Liyuan, and Dr. Song Ruilin for the fourth board of directors [1] Group 2 - The supervisory board proposed the reappointment of current shareholder representative supervisors Ms. Feng Rongli and Mr. Kong Deli for the fourth supervisory board [1] - Ms. Feng Rongli and Mr. Kong Deli will continue to perform their supervisory duties until the temporary shareholders' meeting elects the members of the fourth supervisory board [1] - The current employee representative supervisor Mr. Liu Zhiyong was reappointed for the fourth supervisory board at the employee representative meeting scheduled for August 8, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 建議委任第四屆董事會董事 建議委任第四屆監事會股東代表監事 及 委任職工代表監事 建議重新委任及委任第四屆董事會董事 第三屆董事會的任期於近期屆滿，各董事將繼續履行彼等的董事職責，直至選 舉產生第四屆董事會成員之臨時股東大會結束。 董事會現時由十一名董事組成，包括一名執行董事、六名非執行董事及四名獨立 非執行董事。第三屆董事會的任期於近期屆滿，各董事將繼續履行彼等作為董事 的職責，直至選舉產生第四屆董事會成員之臨時股東大會結束。 董事會建議第四屆董事會由十一名董事組成，其中包括一名執行董事、六名非 執行董事及四名獨立非執行董事。董事會已審議及批准重新委任及委任以下第 四屆董事會董事候選人： 董事會建議(i)重新委任現屆執行董事朱俊博士為第四屆董 ...

Major Events - Silver诺医药-B (02591) is set to conduct an IPO from August 7 to August 12, with an expected listing date of August 15 [1] - Boan Biotech (06955) plans to place 48 million shares at a discount of approximately 8.78%, aiming to raise about HKD 780 million [1] - Derin Holdings (01709) intends to raise HKD 653.3 million, focusing on the development of blockchain, RWA, and virtual asset businesses [1] - Fuhong Hanlin (02696) received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for thymic cancer treatment [1] - China Biopharmaceutical (01177) obtained NMPA approval for the Phase II clinical trial application of LM-24C5, a dual antibody targeting CEACAM5/4-1BB [1] Financial Reports - China Mobile (00941) reported a shareholder profit of HKD 84.235 billion, a year-on-year increase of 5.03% [1] - Manulife Financial-S (00945) announced a core profit of CAD 1.7 billion for the second quarter [1] - Swire Properties (01972) reported a basic profit attributable to shareholders of HKD 4.42 billion, a year-on-year growth of 15% [1] - Hutchison Whampoa (00013) posted a net profit of USD 455 million, a significant year-on-year increase of 1663.32% [1] - MGM China (02282) disclosed a net profit of HKD 2.383 billion, a year-on-year decrease of 11.25% [1] - SMIC (00981) reported a shareholder profit of USD 132 million for the second quarter, with a revenue guidance for the third quarter indicating a sequential growth of 5% to 7% [1] - Zai Lab (09688) achieved a total revenue of approximately USD 216 million for the first half of the year, reflecting a year-on-year growth of 15.35% [1] - Innovent Biologics (01801) reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% [1] - Pacific Basin Shipping (02343) announced a profit attributable to shareholders of USD 25.6 million, a year-on-year decrease of 56% [1] - Lee & Man Paper Manufacturing (02314) reported a net profit of HKD 811 million, a year-on-year increase of 0.7%, with an interim dividend of HKD 0.066 per share [1] - Swire Group reported a profit attributable to shareholders of HKD 815 million for the first half of the year, a year-on-year decrease of 79% [1] - Lee & Man Chemical Company (00746) reported a profit increase of 36.0% to HKD 327 million, with an interim dividend of HKD 0.195 per share [1] - Hua Hong Semiconductor (01347) reported a profit attributable to parent company owners of USD 7.952 million for the second quarter, a year-on-year increase of 19.2% [1] - Wharf Real Estate Investment (01997) reported a loss attributable to shareholders of HKD 2.406 billion, a year-on-year increase of 128.71%, with the first interim dividend of HKD 0.066 per share [1] - Dekang Agriculture (02419) issued a profit warning, expecting a year-on-year increase in fair value adjustments of biological assets to approximately RMB 1.1 billion to 1.4 billion [1] - Mongol Mining (00975) issued a profit warning, anticipating a net loss of approximately USD 15 million to 25 million for the first half of the year, marking a shift from profit to loss [1] - Dongfeng Motor Group (00489) issued a profit warning, expecting a decline in net profit attributable to the parent company of 90% to 95% for the first half of the year [1]

Core Viewpoint - The company, Fuhong Hanlin (02696.HK), has received FDA approval to initiate a Phase 1 clinical trial for HLX43, a targeted PD-L1 antibody-drug conjugate, for the treatment of thymic carcinoma (TC) [1] Group 1 - HLX43 is a novel targeted PD-L1 antibody-drug conjugate developed by the company, combining a licensed DNA topoisomerase I inhibitor small molecule toxin with a self-developed PD-L1 targeting antibody [1] - The company plans to conduct clinical trials for the TC indication in countries such as Australia, Japan, and the United States once conditions are met [1] - As of the announcement date, there are no approved PD-L1 targeted antibody-drug conjugates available globally [1]

复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物)(HLX43)获美国食品药品管 理局(FDA)批准开展用于治疗胸腺癌(TC)的1期临床试验，可继续推进后续临床相关工作。公司拟于条 件具备后于澳大利亚、日本、美国等国家开展胸腺癌(TC)适应症相关临床试验。 ...

智通财经APP讯，复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物)(HLX43) 获美国食品药品管理局(FDA)批准开展用于治疗胸腺癌(TC)的1期临床试验，可继续推进后续临床相关 工作。公司拟于条件具备后于澳大利亚、日本、美国等国家开展胸腺癌(TC)适应症相关临床试验。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 本公司董事會（「董事會」）欣然宣佈，近日，注射用HLX43（靶向PD-L1抗體 偶聯藥物）（「HLX43」）獲美國食品藥品管理局(FDA)批准開展用於治療胸腺 癌(TC)的1期臨床試驗，可繼續推進後續臨床相關工作。本公司擬於條件具 備後於澳大利亞、日本、美國等國家開展胸腺癌(TC)適應症相關臨床試驗。 B. 關於HLX43 HLX43是由本公司利用許可引進的新型DNA拓撲異構酶I抑制劑小分子毒 素－肽鏈連接符與本公司自主研發的靶向PD-L1的抗體進行偶聯開發的靶向 PD-L1的抗體偶聯藥物(ADC)，擬用於晚期/轉移性實體瘤的治療。截至本公 告日，HLX43及相關聯合療法的最新進展情況如下： | 產品/聯合療法 | 適應症 | 最新進展 | | ...

中国生物制药(01177) 自主研发的罗伐昔替尼片"TQ05105 (JAK/ROCK抑制剂)"被纳入突破性治疗药物程 序 复宏汉霖(02696)：HLX79注射液联合汉利康® 治疗活动期肾小球肾炎的2期临床研究于中国境内完成首 例患者给药 瑛泰医疗(01501)拟出资不超过1.1亿元参设怀格广泰基金 晋景新能(01783)建议股份拆细 【财报数据】 国泰航空(00293)发布中期业绩 股东应占溢利36.51亿港元 同比增长1.1% 中期息每股20港仙 【重大事项】 国泰航空(00293)购买十四架波音777-9型飞机 恒瑞医药(01276)：注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺 癌适应症获得美国 FDA孤儿药资格认定 百济神州(06160)发布第二季度业绩 净利润9432万美元 同比扭亏为盈 新鸿基公司(00086)发盈喜 预计中期股东应占溢利同比增加至不低于8亿港元 维信金科(02003)发盈喜，预期中期综合净利润不少于2亿元 同比大幅增长 赤子城科技(09911)发盈喜 预计中期股东应占利润同比增长约108.9%至126.7% 华显光电(00334)发盈喜 预期上半年 ...